EUVIMEDOpdag EUVIMED
Open access

Evidence of active whole-genome doubling (WGD) subclones in non-WGD tumors

Funan He iD, Mehwish Noureen, Eloise Dray iD, Myron S Ignatius iD, Xiaojing Wang iD, Siyuan Zheng iD

Science Advances · 2026-10-30 · 12 (44)

DOI: 10.1126/sciadv.aee7939 ↗

At a glance

Journal article in Science Advances, published on 2026-10-30. Written by Funan He and 5 co-authors. Institution: Greehey Children's Cancer Research Institute, UT Health San Antonio, San Antonio, TX, USA. Major MEDLINE topics: Neoplasms, Genome, Human. 70 references. The full text is freely available in PubMed Central. Funded by: NIEHS NIH HHS, NIGMS NIH HHS, American Cancer Society.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Whole-genome doubling (WGD) occurs frequently in human cancer and influences tumor evolution, metastasis, and treatment response. Here, we integrate bulk, single-cell, and spatial data to dissect the subclonal dynamics of WGD. Single-cell data analysis shows that WGD cells are prevalent even in tumors that are classified as non-WGD (nWGD). WGD subclones actively acquire somatic copy number alterations as they expand, suggesting ongoing evolution. We developed and rigorously validated a gene expression–based method, WAGES, to map WGD cell clonal fraction in bulk tumors. Applying WAGES to nWGD tumors, we reveal genomic correlates including TP53 mutations and chromosomal instability that are consistent with the presence of WGD subclones. Clinically, WAGES scores are strongly correlated with tumor metastatic potential, response to treatments including chemotherapy and immunotherapy, and patient prognosis. These findings reveal widespread WGD subclones in nWGD tumors and demonstrate their substantial impact on cancer evolution and therapeutic outcomes.

Subjects

MeSH terms (MEDLINE)

NeoplasmsGenome, HumanHumansMutationDNA Copy Number VariationsSingle-Cell AnalysisGene Expression Regulation, NeoplasticTumor Suppressor Protein p53Chromosomal InstabilityGenomics

Substances

Tumor Suppressor Protein p53

Authors and institutions

  • Greehey Children's Cancer Research Institute, UT Health San Antonio, San Antonio, TX, USA.
  • Department of Population Health Sciences, UT Health San Antonio, San Antonio, TX, USA.
  • Department of Biochemistry and Structural Biology, UT Health San Antonio, San Antonio, TX, USA.
  • Mays Cancer Center at UT Health San Antonio, San Antonio, TX, USA.
  • Department of Molecular Medicine, UT Health San Antonio, San Antonio, TX, USA.
  • Barshop Institute for Longevity and Aging Studies, UT Health San Antonio, San Antonio, TX, USA.

ORCID profiles: Funan He, Eloise Dray, Myron S Ignatius, Xiaojing Wang, Siyuan Zheng

Funding

  • NIEHS NIH HHS
  • NIGMS NIH HHS
  • American Cancer Society
  • National Institute of General Medical Sciences
  • National Institute of Environmental Health Sciences
  • Cancer Prevention and Research Institute of Texas

Cite

APA

He, F., Noureen, M., Dray, E., Ignatius, M. S., Wang, X., & Zheng, S. (2026). Evidence of active whole-genome doubling (WGD) subclones in non-WGD tumors. Science Advances, 12(44). https://doi.org/10.1126/sciadv.aee7939

Vancouver

He F, Noureen M, Dray E, Ignatius MS, Wang X, Zheng S. Evidence of active whole-genome doubling (WGD) subclones in non-WGD tumors. Science Advances. 2026;12(44). doi:10.1126/sciadv.aee7939

BibTeX
@article{He2026,
  author = {He, Funan and Noureen, Mehwish and Dray, Eloise and Ignatius, Myron S and Wang, Xiaojing and Zheng, Siyuan},
  title = {Evidence of active whole-genome doubling (WGD) subclones in non-WGD tumors},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {44},
  doi = {10.1126/sciadv.aee7939}
}
Start for free →